Dr. John Cush RheumNow
1 year ago
Factors Affecting Biologic Use in Rheumatoid Arthritis
A San Francisco Rheumatoid Arthritis Panel cohort survey between 1999–2011, showed numerous sociodemographic, disease, and health characteristics that influenced the initiation of treatment with biologic agents for https://t.co/azDYk6saHN
Dr. John Cush RheumNow
1 year ago
RHEUM Survey: Starting a new biologic agent in RA, when do you expect to see a good response? CLICK HERE>> https://t.co/NBXu4cNLVj
a.6 weeks
b.3 months
c.4 months
d.6 months
e.With adverse events
Dr. John Cush RheumNow
1 year ago
Cancer screening in RA - retrospective, matched cohort study of 1,614 RA vs 1,597 controls (mean 63 yrs); @ 5 yrs, RA had less cervical cancer screens (52% vs 58%) (aHR:0.83); but no decrease in screens for breast (aHR:0.98), prostate (aHR:0.99), or colorectal (aHR:1.04) CA https://t.co/NnxRnZcZwq
The annual Medscape Physician Compensation report was published and shows only modest salary gains for most specialists.
Dr. John Cush RheumNow
1 year ago
knee osteoarthritis, genicular artery embolization can provide long-lasting pain relief, improved functional outcomes, and enhanced quality of life during a 12-month period. https://t.co/sJuESpvehY
Dr. John Cush RheumNow
1 year ago
"FLAME" - machine learning model developed to predict SLE flares. Data from 28,433 SLE pts (2011-2022) looked at clinical & social determinants of health (SDoH) to predict 3 mo flare risk. AUROC = 0.67; SHAP analysis identified HA, OBS, & pyuria as predictors. Is this the https://t.co/6Eqqc9w2oV
U.S. News & World Report has published its Best Hospitals for 2025, listing the best among many specialties, including rheumatology. Each year, U.S. News ranks hospitals in 15 specialties and for the 8th year in a row, Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report.
Dr. John Cush RheumNow
1 year ago
PsA is worse in women--why? 100 PsA pts, serum study of differentially expressed proteins - 20 times more sex-specific DEPs in PsA males than females (PsA vs controls). In women leukotriene A-4; and in men IL-36, NEK7 & PIK3CA/PIK3R1 were significant predictors. https://t.co/JzI1n6Hf5G
Dr. John Cush RheumNow
1 year ago
CKD & Osteoporosis Rx Revisited (7.25.2025)
Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.
https://t.co/k78DRpWIJS https://t.co/aYKvIhmJN1
Dr. John Cush RheumNow
1 year ago
Heart Attack No Longer the Leading Cause of Death in America . Journal of AHA reports that heart disease mortality in the United States dropped by 66 percent over the past five decades, driven largely by a dramatic decline in fatal heart attacks. https://t.co/whMQSMozVv https://t.co/ik6uydmspF
Lupus nephritis patients on long-term therapy with hydroxychloroquine showed significantly less decline in renal function, compared with patients treated otherwise, a 10-year retrospective study indicated.
A San Francisco Rheumatoid Arthritis Panel cohort survey between 1999–2011, showed numerous sociodemographic, disease, and health characteristics that influenced the initiation of treatment with biologic agents for rheumatoid arthritis (RA).
Dr. John Cush RheumNow
1 year ago
Systemic immune-inflammation index (SII), as a potential biomarker -- computed as platelet count × neutrophil count/lymphocyte count. SII has been shown to be useful in RA, PsA, SpA, SLE and vasculitis, reflecting disease activity, drug responses & supplements ESR & CRP levels https://t.co/LuFaYbWiWN
Dr. John Cush RheumNow
1 year ago
Review of risankizumab efficacy & safety included 545 psoriasis pts showing Mean PASI decreased from 14 to 0.5 at 208Wk. PASI100 achieved in 33% and 74% at 16Wk & 208Wk. Bio-naïve responded faster bio-experienced pts - only 5 pts D/C for adverse events https://t.co/VklLWpD0SF https://t.co/zZfuiFijd4
Dr. John Cush RheumNow
1 year ago
MTX or TNFi use in elderly #RA pts w/in a year of Dx of melanoma was not associated with increased mortality. This included melanoma in situ (48%), localized (47%) and regional (5%) melanoma. Steroid use however was assoc w/ reduced survival. https://t.co/QOXfEf51S1 https://t.co/6BPtEV6sOU
